Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 2/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | PREP | P48147 | 1/20 | 0.33 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 3/20 | 0.33 |
| ▸ | MAOA | P21397 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA5A | P35218 | 1/20 | 0.33 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.32 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2830649 | 0.83 | STS (0.44) | PARP1CA2 | |
| SCHEMBL2767117 | 0.78 | MIF (0.44) | PARP1CYP2D6HDAC4HDAC1HDAC6 | |
| SCHEMBL2783566 | 0.77 | DRD3 (0.46) | PARP1CYP2D6PREPDRD3KCNH2 | |
| SCHEMBL2767286 | 0.75 | MIF (0.45) | PARP1HDAC1DRD3KCNH2 | |
| SCHEMBL2767228 | 0.74 | MIF (0.46) | HDAC1 | |
| SCHEMBL31166902 | 0.72 | MAP2K1 (0.49) | CYP3A4MEN1KMT2A | |
| SCHEMBL31166918 | 0.71 | ABHD6 (0.38) | CYP3A4MEN1KMT2A | |
| SCHEMBL2766527 | 0.71 | MIF (0.54) | HDAC1 | |
| SCHEMBL2766407 | 0.71 | MIF (0.51) | GRM2 | |
| SCHEMBL31167019 | 0.68 | SLC6A2 (0.37) | MEN1KMT2AOPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3142665-B1 | MIF INHIBITORS FOR THE ACUTE OR CHRONIC TREATMENT OF PULMONARY HYPERTENSION | APAXEN (BE) | 2021-01-20 | — | — | EP | disclosed |
| US-10071080-B2 | MIF inhibitors for the acute or chronic treatment of pulmonary hypertension | MIFCARE (FR) | 2018-09-11 | — | — | US | disclosed |
| EP-2944310-B1 | MIF inhibitors for the acute or chronic treatment of pulmonary hypertension | MIFCARE (FR) | 2018-03-21 | — | — | EP | disclosed |
| US-20170079958-A1 | MIF INHIBITORS FOR THE ACUTE OR CHRONIC TREATMENT OF PULMONARY HYPERTENSION | Universite Paris-Saclay (FR) | 2017-03-23 | — | — | US | disclosed |
| EP-3142665-A1 | MIF INHIBITORS FOR THE ACUTE OR CHRONIC TREATMENT OF PULMONARY HYPERTENSION | Mifcare (FR) | 2017-03-22 | — | — | EP | disclosed |
| WO-2015173433-A1 | MIF INHIBITORS FOR THE ACUTE OR CHRONIC TREATMENT OF PULMONARY HYPERTENSION | MIFCARE (FR) | 2015-11-19 | — | — | WO | disclosed |
| EP-2944310-A1 | MIF inhibitors for the acute or chronic treatment of pulmonary hypertension | Mifcare (FR) | 2015-11-18 | — | — | EP | disclosed |
| EP-1805170-B1 | MIF-INHIBITORS | NOVARTIS AG (CH) | 2010-04-14 | — | — | EP | disclosed |
| US-7378416-B2 | MIF-inhibitors | NOVARTIS AG (CH) | 2008-05-27 | — | — | US | disclosed |
| US-20070219189-A1 | MIF-INHIBITORS | NOVARTIS AG (CH) | 2007-09-20 | — | — | US | disclosed |
| EP-1805170-A1 | MIF-INHIBITORS | Novartis AG (CH) | 2007-07-11 | — | — | EP | disclosed |
| WO-2006045505-A1 | MIF-INHIBITORS | NOVARTIS AG (CH) | 2006-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219189-A1 | MIF-INHIBITORS | MIF, FOXM1, CCR8 | GRM2 1639/4885PARP1 2583/4885CYP3A4 365/4885 |
| US-10071080-B2 | MIF inhibitors for the acute or chronic treatment of pulmonary hypertension | MIF, CCL11, PGF | GRM2 2371/4885PARP1 4679/4885CYP3A4 1246/4885 |
| US-20170079958-A1 | MIF INHIBITORS FOR THE ACUTE OR CHRONIC TREATMENT OF PULMONARY HYPERTENSION | MIF, CCL11, PGF | GRM2 2371/4885PARP1 4679/4885CYP3A4 1246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.